Related references
Note: Only part of the references are listed.Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Ivan Fan-Ngai Hung et al.
LANCET (2020)
AKI and Collapsing Glomerulopathy Associated with COVID-19 and APOL1 High-Risk Genotype
Huijuan Wu et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Miriam Merad et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice
Pazit Beckerman et al.
NATURE MEDICINE (2017)
Integrative Genomics Identifies Novel Associations with APOL1 Risk Genotypes in Black NEPTUNE Subjects
Matthew G. Sampson et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1
Brendan Nichols et al.
KIDNEY INTERNATIONAL (2015)
Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans
Giulio Genovese et al.
SCIENCE (2010)
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis
Jeffrey B. Kopp et al.
NATURE GENETICS (2008)
Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: Implications for albuminuria in diabetes
Minghao Ye et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
WH Li et al.
NATURE (2003)
Share Paper
